Screener
Wave Life Sciences WVE Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | (8,322) | (8,055) |
| Deferred revenue | (29,631) | (16,257) |
| Operating lease liabilities | (4,191) | (3,693) |
| Net cash used in operating activities | (113,135) | (109,051) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (1,322) | (471) |
| Purchases of marketable securities | (122,570) | — |
| Net cash used in investing activities | (123,892) | (471) |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's operating cash flow?
- Wave Life Sciences (WVE) reported operating cash flow of -$53.58M in Q2 2026.
- How has Wave Life Sciences's operating cash flow changed year-over-year?
- Wave Life Sciences's operating cash flow decreased by 16.5% year-over-year, from -$46.01M to -$53.58M.
- What is the long-term trend for Wave Life Sciences's operating cash flow?
- Over 3 years (2021 to 2025), Wave Life Sciences's operating cash flow has grown at a 28.2% compound annual growth rate (CAGR), from -$88.99M to -$187.49M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Wave Life Sciences's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude